Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM-201 is a personalized nanoparticle formulation of paclitaxel being developed by LipoMedics. It utilizes the company's proprietary phospholipid-bound nanoparticle platform (based on LM-101) in conjunction with a Therapeutic Drug Monitoring (TDM) device to enable individualized dosing. Paclitaxel acts as a microtubule stabilizer by targeting tubulin, thereby inhibiting cell division and inducing apoptosis in cancer cells. The TDM-guided approach is designed to optimize drug exposure and minimize toxicity by accounting for patient-specific pharmacokinetic variability. LM-201 is intended for the treatment of various solid tumors, including metastatic breast cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer (NSCLC).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LM-201.